CA-NEXON-AMERICA-INC
The highly-anticipated free to play kart racing game, KartRider: Drift , will hold its second Closed Beta starting June 3, 2020 via the Nexon Launcher, Steam, and Xbox One, including Xbox One X delivering cross-platform play. Players can register here for a chance to join the second Closed Beta starting today!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005906/en/
Players invited to the second Closed Beta will receive an acceptance email, and they can pre-download the game starting on June 1, 2020 at 7 p.m. PDT. Players who participated in the first Closed Beta will automatically be included.
During the Closed Beta period, players will be introduced to a new character — Diz, as well as new skins for existing characters, plus additional karts and tracks. The Closed Beta will also showcase new functions such as Racing Pass and a new Racing School single-player mode, where new and experienced players can improve their racing skills.
Customization will be a huge part of this Closed Beta with the preview of the new wraps, which allows racers to paint their karts and create unique designs for maximum personalization. Participants will also have access to kart upgrades including choice of license plate and can decorate their karts with a lineup of new accessory balloons and character emotes.
Players will also see a revamped User Interface with a new HUD and contextual rear view mirror. The matchmaking experience has also been improved as players will be queued based on their performance in the tutorial. Driving physics of the game have also been improved since the first Closed Beta for a better racing experience.
To reward players who log in during the Closed Beta, special login rewards including a Turbo Tortoise Kart, Bunny Buggy Kart, Simian Scrapper Kart, and Deuce Coupe Kart will be unlocked. All Beta participants will also receive a White Cloud Balloon item at official launch.
Players who sign up for Closed Beta 2 at www.kartriderdrift.net will be in for a treat as KartRider: Drift has partnered with HyperX, ViewSonic and DXRacer, for an opportunity to win exclusive prizes.
KartRider: Drift’s Closed Beta will be available worldwide on the Nexon Launcher, Steam, Xbox One, including Xbox One X, with the exception of Japan, and China on console. To see a full list of available regions, please follow this link .
For more information on KartRider: Drift , visit www.kartriderdrift.net or follow @KartRiderDrift on Twitter for the latest updates and information on contests and giveaways.
Social Media: Facebook / Twitter / Instagram / Discord / Official Site
Press Assets:
About KartRider: Drift http://kartrider.nexon.net/
Launched in 2004, KartRider is a massively popular multiplayer racing franchise that boasts more than 300 million PC players. Making its debut to western audiences, KartRider: Drift takes inspiration from earlier iterations of the game, delivering competitive drift-fueled racing action, featuring different game modes, and deep character + kart customization. Available completely for free on PC Steam, Xbox One, including Xbox One X, and Nexon Launcher (PC), KartRider: Drift offers cross-platform capabilities to challenge friends regardless of the platform they choose or where they are in the world.
About Nexon America Inc. http://www.nexon.net/corporate/about-nexon/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005906/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom